Results 141 to 150 of about 54,075 (219)

Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre-Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. [PDF]

Cancer Med
Xie X, Huang D, Huang J, Chen X, Bai X, Zheng W, Chen L, Lan X, Song L, Lei R, Du C.   +10 more
europepmc   +1 more source

Preventive strategies against brain metastases: current state of the art and future directions. [PDF]

Neurol Res Pract
Ippen FM, Konen FF, Hau P, Winkler F.
europepmc   +1 more source

Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report. [PDF]

Gynecol Oncol Rep
Barr AP, Nakamura N, Nguyen NT.
europepmc   +1 more source

A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib. [PDF]

Front Oncol
Zhang L, Li C, Song S, Wang F, Ding T, Liu Z, Jin Y, Yu Z.   +7 more
europepmc   +1 more source

'Patients are left not knowing': Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer-a qualitative study of patient experience. [PDF]

Support Care Cancer
Dolgilevica K, Chapman B, Derakshan N.
europepmc   +1 more source

Fam-trastuzumab deruxtecan in a patient with metastatic human epidermal growth factor receptor 2-positive breast cancer and pre-existing cardiac failure: a case report. [PDF]

AME Case Rep
Alnan M, Alharbi R.
europepmc   +1 more source

Real-World Outcomes of First-Line Pertuzumab, Trastuzumab, and Taxane in HER2-Positive Metastatic Breast Cancer in Costa Rica: A Multicenter Retrospective Study. [PDF]

Cureus
Priyanka K, Landaverde DU.
europepmc   +1 more source

Protective effects of beta-blockers against anthracycline- and trastuzumab-related cardiotoxicity: a systematic review based on conventional and Bayesian network meta-analysis. [PDF]

Front Cardiovasc Med
Jiang S, Gao G.
europepmc   +1 more source

Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure. [PDF]

Breast
Kemik F, Şahin TK, Özçelik H, Sezer A, Başaran G, Açıkel Yüksel SD, Güney G, Yıldız I, Er Ö, Korkmaz T, Biter S, Erdem D, Tünbekici S, Oruç A, Güren AK, Kaban K, Aykan MB, Ekinci ÖB, Deliktaş Onur I, Kalem A, Altunok O, Seyyar M, Güney B, Akdoğan O, Yazıcı M, Majidova N, Türker S, Köylü B, Kıkılı CI, Demir N, Tunalı D, Laçin Ş, Tural D, Bilici A, Bayram E, Göker E, Araz M, Bayoğlu IV, Molinas Mandel N, Karadurmuş N, Çelik E, Ateş Ö, Yeşil Çınkır H, Yılmaz M, Gürsu RU, Yazıcı O, Çabuk D, Güven DC, Selçukbiricik F, Aksoy S, Gündüz Ş.   +50 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia. [PDF]

J Health Econ Outcomes Res
Samacá-Samacá D, Ballén D, Lombana M, Díaz-Puentes M, Cáceres-Maldonado SA, Saavedra J, Prieto-Pinto L.   +6 more
europepmc   +1 more source